In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The New Math of Drug-Device Convergence

Executive Summary

In combination products that span the device and pharmaceutical industry, one plus one doesn't necessarily equal three. Speaking at "Convergence: the Drug/Device Summit," Paul LaViolette, chief operating office of Boston Scientific, recounts the intricacies of getting Taxus, the largest combination product in history, to market. For all the success BSC has had, both with Taxus and generally speaking--a huge infrastructure, billions of dollars in revenues, and 18 PMA approvals under its belt-the first lesson it learned from its drug-eluting stent program was, "As hard as you think it may be, it's harder than that."

You may also be interested in...



Gauging the Risks of Financing Convergence Start-Ups

A handful of recent biotech-device company deals have highlighted the potential of drug-device convergence as natural extensions of the ever-popular repurposing and drug delivery models espoused by investors aiming to reduce the risks associated with drug discovery. Venture capitalists are eager to get in on the game, but drug and device hybrid business models are few and far between. True convergence start-ups remain thin on the ground, a fact VCs say reflects the additive nature of drug risk and device risk.

Sanofi Bags EU Approvals But Fumes At Regulator

Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

IV002557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel